Berry Oncology, a global leading company specialized in genomic testing and early cancer screening, announced the launch of its innovative one-time precision product HIFI Pan-Cancer Screening, which is an early multi-cancer screening product developed based on the company’s proprietary HIFI technology platform. With one single testing, the product can accurately detect 6 high-risk and high-incident cancers in China that include lung cancer, esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, and colorectal cancer, with a global leading performance of 87.58% sensitivity, 99.09% specificity and 82% traceability accuracy.
Also Read: Devyser Wins Breakthrough Contract in Canada for Non-invasive Fetal RHD testing
Cancer has become a global public health challenge. According to the 2020 global cancer burden data released by the International Agency for Research on Cancer (IARC), there were 19.29 million new cancer cases and 9.96 million cancer deaths worldwide in 2020, while the numbers in China were 4.57 million and 3 million respectively in the same year, ranking the first in the world which has imposed a heavy disease burden on individuals and society.
The Healthy China 2030 Plan, issued by the Central Committee of the Communist Party of China and the State Council, clearly states that early diagnosis and treatment of major high-risk cancers is highly encouraged, opportunistic cancer screening should be promoted, and the 5-year overall cancer survival rate in China is expected to be increased by 15% by 2030. In the recently released 14th Five-Year Plan for Bioeconomic Development, it also stated that it is necessary to incorporate advanced technologies such as genetic testing into disease prevention, and to carry out early screening for major diseases such as cancers, so as to provide precision solutions and decision support for individualized treatment.
NGS-based liquid biopsy technology has greatly improved the possibility of early cancer screening. On top of significant improvement in the overall testing performance, innovative liquid biopsy products for early cancer screening, taking HIFI Pan-Cancer Screening as an example, have accessible benefits of minimal invasiveness and user friendliness, which help increase the compliance of high-risk groups and create bigger clinical intervention window for patients with early-stage cancer to improve their survival rate, compared with traditional cancer screening methods such as tumor markers and imaging.